---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-100790"
form_type: "8-K"
ticker: "RNLXY"
cik: "0001811115"
company_name: "Renalytix plc"
filed_at: "2024-08-27T23:59:59+00:00"
generated_at: "2026-05-31T07:26:53.196882+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Renalytix gets Nasdaq extension to Oct 25, 2024; transfers to Capital Market

## Summary
- Nasdaq Hearings Panel grants until October 25, 2024 to regain compliance with minimum bid price of $1.00.
- ADSs transfer from Nasdaq Global Market to Nasdaq Capital Market effective August 27, 2024.
- Must also achieve $2.5M minimum stockholders' equity and provide 12-month income projections.
- Unaudited cash position $4.7M as of June 30, 2024; cash runway into Q4 2024.
- Advanced discussions with stakeholders for funding and refreshed business plan.

## SEC filing metadata
- accession: 0000950170-24-100790
- form_type: 8-K
- ticker: RNLXY
- cik: 0001811115
- company_name: Renalytix plc
- filed_at: 2024-08-27T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811115/000095017024100790/0000950170-24-100790-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811115/000095017024100790/rnlx-20240823.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-100790
- JSON: https://secwatch.observer/filing/0000950170-24-100790.json
- Plain text: https://secwatch.observer/filing/0000950170-24-100790.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.